Skip Navigation

A Randomized Phase II Study of CDX-1127 Varlilumab in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-cell Lymphomas

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT03038672

Study #:
STUDY00146232

Start Date:
Oct 21, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03038672

View Complete Trial Details & Eligibility at ClinicalTrials.gov